WESTBROOK, Maine / Feb 20, 2024 / Business Wire / IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences:
Individuals can access the live audio webcasts of the presentations through links on the IDEXX website, www.idexx.com/investors. An archived edition of the presentations will be available via the same link.
About IDEXX Laboratories, Inc.
IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs nearly 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit www.idexx.com.
Last Trade: | US$404.02 |
Daily Change: | -0.63 -0.16 |
Daily Volume: | 931,250 |
Market Cap: | US$33.080B |
February 03, 2025 October 31, 2024 August 21, 2024 August 06, 2024 June 04, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load